Engineered immune cells take on hard-to-treat blood cancer

This study tests a new treatment called S101 for people with a rare and aggressive blood cancer (T-Lymphoblastic Leukemia/Lymphoma) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a specific marker (CD7). The goal is to see if this therapy can shrink tumors or clear cancer from the bone marrow, and to check for side effects. About 38 participants will be enrolled.